Cited by

• A tool for safer prescribing in vulnerable adults: the continuing development of the Medichec app and website.

  Bishara D, Riaz S, Sauer J, Mueller C, Gee S, Taylor D, Wilcha RJ, Edwards M, Beehuspoteea N, Mallia AMB, Brook J, Balasundaram B, Harwood D, Funnell N, Strydom A, Stewart R. Bishara D, et al. BJPsych Bull. 2023 Sep 6;48(4):1-7. doi: 10.1192/bjb.2023.71. Online ahead of print. BJPsych Bull. 2023. PMID: 37671832 Free PMC article. Review.
• Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis.

  Naseri A, Sadigh-Eteghad S, Seyedi-Sahebari S, Hosseini MS, Hajebrahimi S, Salehi-Pourmehr H. Naseri A, et al. Dement Neuropsychol. 2023 May 29;17:e20220053. doi: 10.1590/1980-5764-DN-2022-0053. eCollection 2023. Dement Neuropsychol. 2023. PMID: 37261256 Free PMC article. Review.
• A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO).

  Madan A, Brown T, Ray S, Agarwal P, Roy-Faderman I, Burdick D. Madan A, et al. Cureus. 2022 Nov 23;14(11):e31818. doi: 10.7759/cureus.31818. eCollection 2022 Nov. Cureus. 2022. PMID: 36425049 Free PMC article.
• Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly.

  Bankes DL, Jin H, Finnel S, Michaud V, Knowlton CH, Turgeon J, Stein A. Bankes DL, et al. Pharmacy (Basel). 2020 May 20;8(2):87. doi: 10.3390/pharmacy8020087. Pharmacy (Basel). 2020. PMID: 32443719 Free PMC article.
• Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.

  Sui W, Li H, Yang Y, Jing X, Xue F, Cheng J, Dong M, Zhang M, Pan H, Chen Y, Zhang Y, Zhou Q, Shi W, Wang X, Zhang H, Zhang C, Zhang Y, Cao Y. Sui W, et al. Proc Natl Acad Sci U S A. 2019 May 28;116(22):10937-10942. doi: 10.1073/pnas.1901655116. Epub 2019 May 13. Proc Natl Acad Sci U S A. 2019. PMID: 31085638 Free PMC article.